Kazia Therapeutics is pleased to announce a collaboration with QIMR Berghofer Medical Research Institute, one of Australia’s foremost cancer research centers, to explore novel uses of paxalisib in solid tumours. The research project is led by Professor Sudha Rao, a leading expert in transcriptional biology, particularly as it applies to the function of the immune system in cancer. Professor Rao’s laboratory works closely with pharmaceutical companies and with clinicians to explore innovative approaches to cancer treatment. The collaboration is ongoing and will build on initial research that has already led to the filing of a patent, including the use of paxalisib as an immune modulator in the treatment of diseases such as breast cancer. It is anticipated that the results of the research will be published in 1H CY2023, and discussions are ongoing regarding potential translation to clinical trials in CY2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KZIA:
